Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Metastasis | Research article

Role of intraparotid node metastasis in mucoepidermoid carcinoma of the parotid gland

Authors: Xingyu Niu, Qigen Fang, Fei Liu

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstracts

Background

Prognostic factors for parotid mucoepidermoid carcinoma (MEC) usually include disease grade, tumor stage, node stage, perineural invasion, and lymphovascular invasion. But the role of intraparotid nodes (IPNs) remains unclear, therefore, the study aimed to analyze the significance of IPNs in predicting recurrence in parotid MEC.

Methods

One hundred and ninety patients were included for analysis finally. Data regarding demography, pathological characteristics, IPN metastasis, TNM stage, follow up was collected and evaluated. The recurrence-free survival (RFS) was the main study endpoint.

Results

A total of 47 (24.7%) patients had IPN metastasis, and the IPN metastasis was significantly related to tumor stage, pathologic N stage, lymph-vascular invasion, perineural invasion, and disease grade. Recurrence occurred in 34 (17.9%) patients. For patients without IPN metastasis, the 10-year RFS rate was 88%, for patients with IPN metastasis, the 10-year RFS rate was 54%, the difference was significant (p < 0.001). Further Cox model analysis confirmed the independence of IPN metastasis in predicting the prognosis.

Conclusion

The IPN metastasis is relatively common in parotid MEC, it is significantly related to tumor stage and disease grade, IPN metastasis means worse recurrence-free survival.
Literature
1.
Terhaard CH, Lubsen H, Van der Tweel I. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck. 2004;26:681–92.CrossRefPubMed
2.
Barnes LEJRP, Sidransky D. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. IARC. IARC: Lyon; 2005.
3.
Barnes LEJ, Reichart P, Sidransky D. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. IARC. IARC: Lyon; 2005.
4.
Szewczyk M, Golusiński P, Pazdrowski J, Pieńkowski P, Marszałek S, Sygut J, Golusiński W. Patterns of treatment failure in salivary gland cancers. Rep Pract Oncol Radiother. 2018;23:260–5.CrossRefPubMed
5.
Nisa L, Borner U, Dür C, Arnold A, Giger R. Recurrent parotid gland carcinoma: how effective is salvage surgery? Eur Arch Otorhinolaryngol. 2018;275:507–13。.CrossRefPubMed
6.
Scherl C, Kato MG, Erkul E, Graboyes EM, Nguyen SA, Chi AC, Morgan PF, Day TA. Outcomes and prognostic factors for parotid acinic cell carcinoma: a National Cancer Database study of 2362 cases. Oral Oncol. 2018;82:53–60.CrossRefPubMed
7.
Pisani P, Ramponi A, Pia F. The deep parotid lymph nodes: an anatomical and oncological study. J Laryngol Otol. 1996;110:148–50.CrossRefPubMed
8.
Klussmann JP, Ponert T, Mueller RP, Dienes HP, Guntinas-Lichius O. Patterns of lymph node spread and its influence on outcome in resectable parotid cancer. Eur J Surg Oncol. 2008;34:932–7.CrossRefPubMed
9.
Lau VH, Aouad R, Farwell DG, Donald PJ, Chen AM. Patterns of nodal involvement for clinically N0 salivary gland carcinoma: refining the role of elective neck irradiation. Head Neck. 2014;36:1435–9.CrossRefPubMed
10.
Lim CM, Gilbert MR, Johnson JT, Kim S. Clinical significance of intraparotid lymph node metastasis in primary parotid cancer. Head Neck. 2014;36:1634–7.CrossRefPubMed
11.
Nisa L, Salmina C, Dettmer MS, Arnold A, Aebersold DM, Borner U, Giger R. Implications of intraglandular lymph node metastases in primary carcinomas of the parotid gland. Laryngoscope. 2015;125:2099–106.CrossRefPubMed
12.
Sönmez Ergün S, Gayretli O, Büyükpınarbaşılı N, Yıldız K, Gürses IA, Avşar A, Cavlak M. Determining the number of intraparotid lymph nodes: postmortem examination. J Craniomaxillofac Surg. 2014;42:657–60.CrossRefPubMed
13.
Lima RA, Tavares MR, Dias FL, Kligerman J, Nascimento MF, Barbosa MM, Cernea CR, Soares JR, Santos IC, Salviano S. Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg. 2005;133:702–8.CrossRefPubMed
14.
Shinomiya H, Otsuki N, Yamashita D, Nibu K. Patterns of lymph node metastasis of parotid cancer. Auris Nasus Larynx. 2016;43:446–50.CrossRefPubMed
15.
Stenner M, Molls C, Luers JC, Beutner D, Klussmann JP, Huettenbrink KB. Occurrence of lymph node metastasis in early-stage parotid gland cancer. Eur Arch Otorhinolaryngol. 2012;269:643–8.CrossRefPubMed
16.
Stodulski D, Mikaszewski B, Majewska H, Wiśniewski P, Stankiewicz C. Probability and pattern of occult cervical lymph node metastases in primary parotid carcinoma. Eur Arch Otorhinolaryngol. 2017;274:1659–64.CrossRefPubMed
17.
Rajasekaran K, Stubbs V, Chen J, Yalamanchi P, Cannady S, Brant J, Newman J. Mucoepidermoid carcinoma of the parotid gland: a National Cancer Database study. Am J Otolaryngol. 2018;39:321–6.CrossRefPubMed
18.
Armstrong JG, Harrison LB, Thaler HT. The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer. 1992;69:615–9.CrossRefPubMed
19.
Shi S, Fang Q, Liu F, Zhong M, Sun C. Prognostic factors and survival rates for parotid duct carcinoma patients. J Craniomaxillofac Surg. 2014;42:1929–31.CrossRefPubMed
20.
Zbären P, Schüpbach J, Nuyens M, Stauffer E, Greiner R, Häusler R. Carcinoma of the parotid gland. Am J Surg. 2003;186:57–62.CrossRefPubMed
21.
22.
23.
24.
Safdieh J, Givi B, Osborn V, Lederman A, Schwartz D, Schreiber D. Impact of adjuvant radiotherapy for malignant salivary gland tumors. Otolaryngol Head Neck Surg. 2017;157:988–94.CrossRefPubMed
25.
Lee A, Givi B, Osborn VW, Schwartz D, Schreiber D. Patterns of care and survival of adjuvant radiation for major salivary adenoid cystic carcinoma. Laryngoscope. 2017;127:2057–62.CrossRefPubMed
26.
Erovic BM, Shah MD, Bruch G, Johnston M, Kim J, O'Sullivan B, Perez-Ordonez B, Weinreb I, Atenafu EG, de Almeida JR, Gullane PJ, Brown D, Gilbert RW, Irish JC, Goldstein DP. Outcome analysis of 215 patients with parotid gland tumors: a retrospective cohort analysis. J Otolaryngol Head Neck Surg. 2015;44:55.CrossRefPubMedPubMedCentral
Metadata
Title
Role of intraparotid node metastasis in mucoepidermoid carcinoma of the parotid gland
Authors
Xingyu Niu
Qigen Fang
Fei Liu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5637-x

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Study protocol

Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study

Research article

Androgen receptor and FOXA1 coexpression define a “luminal-AR” subtype of feline mammary carcinomas, spontaneous models of breast cancer

Technical advance

Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells

Case report

Prostate cancer solitary metastasis to anal canal: case report and review of literature

Research article

BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer

Case report

Intussusception reveals MUTYH-associated polyposis syndrome and colorectal cancer: a case report
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits